Mayumi Fujita
Physician at Iola Ct, Englewood, CO
License number
Colorado 40553
Issued Date
May 15, 2002
Renew Date
May 1, 2015
Expiration Date
Apr 30, 2017
Type
Physician
Address
Address
6274 S Iola Ct, Englewood, CO 80111
Personal information
See more information about Mayumi Fujita at radaris.comName
Address
Phone
6274 S Iola Ct, Englewood, CO 80111
Denver, CO
1665 Ursula St, Aurora, CO 80010
6040 Gun Club Rd, Aurora, CO 80016
6274 Iola Ct, Englewood, CO 80111
Professional information
See more information about Mayumi Fujita at trustoria.com
Dual Inhibition Of Immunophilin/Cyclophilin Family Members And Emmprin Immunoglobulin Receptor Superfamily Members
Dual Inhibition Of Immunophilin/Cyclophilin Family Members And Emmprin Immunoglobulin Receptor Superfamily Members
US Patent:
2010027, Nov 4, 2010
Filed:
Feb 6, 2010
Appl. No.:
12/701560
Inventors:
Asokan Rengasamy - Aurora CO, US
Mayumi Fujita - Englewood CO, US
Elan Z. Eisenmesser - Denver CO, US
Karen R. Jonscher - Centennial CO, US
David A. Norris - Greenwood Village CO, US
Li Li - Centennial CO, US
Mayumi Fujita - Englewood CO, US
Elan Z. Eisenmesser - Denver CO, US
Karen R. Jonscher - Centennial CO, US
David A. Norris - Greenwood Village CO, US
Li Li - Centennial CO, US
International Classification:
A61K 39/395, A61K 31/713, A61P 17/06, A61P 29/00, A61P 35/00, A61P 9/00
US Classification:
4241361, 514 44 A, 4241721
Abstract:
The present disclosure provides methods and compositions for modulating an adaptive immune response without significantly affecting an innate immunity response in a subject by modulating a combination of an Immunophilin/Cyclophilin Family Member and an EMMPRIN Immunoglobulin Receptor Superfamily Member. The present invention also provides methods and compositions for treating a variety of clinical conditions by modulating an Immunophilin/Cyclophilin Family Member and an EMMPRIN Immunoglobulin Receptor Superfamily Member.
Treatment And Prevention Of Skin Injury Due To Exposure To Ultraviolet Light
Treatment And Prevention Of Skin Injury Due To Exposure To Ultraviolet Light
US Patent:
2009016, Jul 2, 2009
Filed:
Dec 15, 2008
Appl. No.:
12/335110
Inventors:
Lawrence D. Horwitz - Englewood CO, US
Mayumi Fujita - Englewood CO, US
David A. Norris - Englewood CO, US
Mayumi Fujita - Englewood CO, US
David A. Norris - Englewood CO, US
International Classification:
A61K 8/36, A61K 31/197, A61Q 17/04
US Classification:
424 59, 514562
Abstract:
Photoprotective agents useful for the treatment or prevention of cell damage, particularly skin injury due to UV-light. Methods of prevention or treatment of cell damage and skin injury due to exposure to UV-light, particularly UVB-light. Methods include administration of an effective amount of one or more photoprotective N-mercaptoalkanoylcysteine derivatives of this invention, particularly bucillamine or a salt or solvate thereof, to a mammal, particularly a human, which has been or will be exposed to UV-light. Administration may be oral, topical or parenteral.
Biomarkers Of Cancer
Biomarkers Of Cancer
US Patent:
2013022, Aug 29, 2013
Filed:
Aug 16, 2011
Appl. No.:
13/817215
Inventors:
Mayumi Fujita - Englewood CO, US
Charles A. Dinarello - Boulder CO, US
Yuchun Luo - Denver CO, US
William A. Robinson - Denver CO, US
David A. Norris - Englewood CO, US
Charles A. Dinarello - Boulder CO, US
Yuchun Luo - Denver CO, US
William A. Robinson - Denver CO, US
David A. Norris - Englewood CO, US
International Classification:
C12Q 1/68, G01N 33/68
US Classification:
506 9, 435 612, 436501, 435 71
Abstract:
Disclosed is an IL-37 biomarker of cancer and methods of using the biomarker, including methods for diagnosis of cancer, methods of determining predisposition to cancer, methods of monitoring progression/regression of cancer, methods of assessing efficacy of compositions for treating cancer, as well as other methods based on the use of this cancer biomarker.